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ABSTRACT
Alzheimer’s disease (AD), identified over 100 years ago and intensively
studied since the 1970s, has no effective treatments or mechanistic
understanding of the underlying neurodegenerative process. Most investigators
believe accumulation or aggregation of amyloid beta (A) proteins plays a
causative role. Aβ peptides (~39-43 residues) are generated by proteolysis of the
transmembrane protein APP. One reason we know so little about AD is an
incomplete understanding of the cellular mechanisms responsible for A
proteotoxicity. Human ES and iPSC models of AD are recent additions to many
other models used to investigate these mechanisms. AD, however is a chronic
progressive condition of old age and cultured neurons may not live long enough
to model what goes wrong in neurons from AD patients. In my research, I used
hESCs which directly express A peptides thus avoiding the time it takes to
process APP. One App allele in H9 hESCs was previously edited using TALEN.
A homologous recombination cassette coding directly for a secretory form of
either A1-42 or A1-40 and containing a stop codon, was inserted into the first
exon of App upstream of the normal translational start site. I used multiple
independently isolated clones of edited cells with 3 genotypes: App/App
(unedited), App/Aβ1-40 and App/Aβ1-42. Expression of A from edited alleles was
confirmed by qRT-PCR using primers specific for the edit. I first sought to
establish if editing changed any aspects of neuronal differentiation in culture. All
3 genotypes have similar embryoid body (EB) development, and similar numbers
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and sizes of neuronal clusters (NC) up to 34 days after EB dissociation and
neural differentiation. Immunostaining of neuronal markers, NeuN and DCX
(doublecortin), likewise revealed no difference among edited and unedited cells,
suggesting that the edits do not affect the ability of my stem cells to differentiate
into neurons. I next measured accumulation of aggregated A using an
aggregate specific antibody, 7A1a. Data at 34-days post EB dissociation
indicates NCs in the Aβ1-42 edited cells accumulate significantly more aggregates
relative to either unedited or A-40 edited lines, a result consistent with the
increased ability for A1-42 to form aggregates. Aβ aggregates also appear to be
concentrated around fragmented nuclei within neuronal clusters suggesting that
intracellular accumulation may play a key role in proteotoxicity. Additionally, I
observed a significant decrease in the number of synapsin1 puncta, a marker of
synapses, another feature of AD. I documented a nearly 3-fold greater neuronal
cell death in both the Aβ1-40 and Aβ1-42 neurons at 70 days after differentiation.
RNA sequencing data also shows independently isolated clones group together
and show differential expression of genes related to memory and neuronal cell
death. The early presence of Aβ aggregation and subsequent cell death is in line
with the chronic and progressive nature of AD and this is the first known model to
exhibit a neurodegenerative phenotype. These isogenic cell lines thus appear to
be useful to screen for therapeutics that may prevent or slow A1-42 dependent
neurodegeneration and a tool to investigate A-dependent mechanisms with
relevance to AD.
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CHAPTER ONE
ALZHEIMER’S IS A CHRONIC, PROGRESSIVE,
AND COMPLEX DISEASE

Background
Alzheimer’s Disease (AD) is the most common form of dementia and the
6th leading cause of death in the United States (“FastStats - Leading Causes of
Death,” 2016). Symptoms include memory loss, cognitive impairment, behavioral
changes, depression, and progressive neurodegeneration. The number of
affected individuals is expected to increase almost four-fold by 2050 (Hebert,
Weuve, Scherr, & Evans, 2013). While AD is devastating for patients, it also
places burdens on their families, caregivers, and society. The average time from
diagnosis to death is eight years and not every family has the insurance or
financial resources to support the costs of long-term care often required for AD
patients. While a patient’s family can usually act as caregivers in the early stages
of the disease, professional care or hospitalization is required as the disease
progresses. The cost of long term care for patients is expensive and families
frequently rely on inadequately funded public support programs. The emotional
burdens belong only to the patient and their family but the financial burden is
often shared by both the family and society.
Despite intensive research since the 1970s no cure or effective treatment
has been found for AD. Part of the difficulty in finding an effective treatment lies
with how little we understand about the mechanism of amyloid beta (Aβ) toxicity
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in AD. This mechanism has been difficult to establish in part because
accumulation of Aβ precedes its downstream pathological effects in the brain
which may take decades to develop. An additional problem is that most
laboratory AD models do not show significant neurodegeneration as part of their
phenotype even though this is the major cellular aspect of the disease (Bales,
2012).

Neuropathology
Alois Alzheimer, in his discussion of his patient Auguste D., recognized
two hallmark neuropathological lesions: senile plaques and neurofibrillary tangles
(NFTs). These remain the best established post-mortem diagnostic criteria for
AD. Plaques are primarily extracellular aggregates composed of several protein
and non-protein components, but their major constituent is a small neurotoxic
peptide called Aβ1-42. NFTs are intracellular aggregates of a hyperphosphorylated
form of microtubule associated protein tau.
Plaque numbers, despite being a hallmark lesion of AD, don’t correlate
strongly with AD symptoms such as memory loss or early stages of dementia.
They accumulate in the brain of AD patients before tangles in both AD and AD
models and are often a feature of non-affected brains in older individuals.
Tangles, while correlating better with symptoms, are not unique to AD but are a
characteristic lesion of many other neurodegenerative (ND) diseases referred to
as tauopathies (Serrano-Pozo, Frosch, Masliah, & Hyman, 2011).
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Proteolytic Production of Aβ
The A1-42 peptide found in plaques is generated by proteolysis of a large
transmembrane protein, amyloid precursor protein (APP) along with several other
A peptides of differing length (39-43 amino acids) as well as other APP
fragments (Haass, Kaether, Thinakaran, & Sisodia, 2012). The first step in the
amyloidogenic pathway is cleavage of the extracellular domain by an enzyme
called β-secretase. In the second step, a large 4 component protease, secretase, cleaves the APP in the intramembranous region (Figure 1). The most
common peptide is A1-40 along with A1-42. Significantly, rare autosomal
dominant genetic forms of AD contain mutations in either the App gene itself or in
two other genes (Psen1 or Psen2) which form the active proteolytic site of secretase. In addition to this pathogenic amyloid processing pathway there is an
additional proteolytic pathway (non-amyloidogenic) which does not appear to be
involved in AD. This non-amyloidogenic pathway starts with an initial cleavage of
APP at a site within the N-terminus of A1-42 thus preventing Aβ formation via secretase.

3

Figure 1. Aβ Formation via the Amyloidogenic Pathway.
In the amyloidogenic pathway β-secretase first cleaves APP and
subsequently γ-secretase, resulting in 39-43 amino acid-long Aβ
formation. The reason for the range in the length of Aβ peptides
produced is that the active site in -secretase (PSEN1 or PSEN2) is
not precise in its cleavage of APP, but the most common Aβ
peptides formed are Aβ1-40 and Aβ1-42. In the non-amyloidogenic
pathway (bottom), α-secretase first cleaves APP within the Aβ
sequence which prevents subsequent cleavage by-secretase and
Aβ formation.
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Where is Aβ Produced?
Aβ is generated both extracellularly at the plasma membrane as well as
intracellularly in the endoplasmic reticulum (ER), Golgi, lysosomes, and
endosomes although the quantitative importance of production at these different
sites is not known (Choy, Cheng, & Schekman, 2012; Hartmann et al., 1997;
Sisodia, 1992).
Both A1-42 and A1-40 are known to form a variety of oligomeric and higher
ordered aggregated structures. Many investigators believe that oligomeric A1-42
is the primary toxic form, consistent with its increased tendency to form
aggregates relative to A1-40. This may be a result of A1-42 being more
hydrophobic by having an additional C-terminal Leucine and Alanine residues
(Kang et al., 1987; Soto, Brahes, Alvarez, & Inestrosa, 1994). The mechanism of
toxicity however is still not understood. Data is available for altered mitochondrial
function, microtubule structure, ion channels, and various components of the
intracellular membrane trafficking pathways such as autophagy, endosomal and
lysosomal vesicles (C Ballatore, Lee, & J, 2007; Kanae Iijima-Ando et al., 2009;
Lin, Bhatia, & Lal, 2001; Martinez-Vicente, 2015). Aβ production as well as
aggregation is consistently observed in intracellular vesicles but it is still debated
if this compartment plays a primary role in toxicity or if the extracellular Aβ
plaques are more important. Notably, conditions favorable for in vitro Aβ
oligomerization include a high concentration of Aβ peptide and an acidic
environment, both of which are not likely present in extracellular compartments
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but common in intracellular organelles such as lysosomes and late endosomes
(Hu et al., 2009). Additionally, intracellular Aβ accumulation appears before
extracellular accumulation and the ER is the main site of intracellular Aβ
oligomerization (Meli et al., 2014; Oddo, Caccamo, Smith, Green, & LaFerla,
2006).

Tau Tangle Formation and Its Pathological Appearance in AD
Tau, also known as neuronal microtubule associated protein tau, normally
plays a role in the outgrowth of neuronal processes by promoting microtubule
stability and assembly (Z. Liu et al., 2015). Association of tau with microtubules is
mostly dependent on its phosphorylation status. Unphosphorylated tau attaches
readily to microtubules and promotes their stability. Phosphorylation of Tau
causes separation from microtubules which allows cellular cargo to pass (Carlo
Ballatore, Lee, & Trojanowski, 2007). Hyper-phosphorylation of tau at specific
sites creates unstable microtubules and cytoplasmic tau begins to form paired
helical filaments that aggregate into NFTs within the cell (Z. Liu et al., 2015;
Virginia M.-Y. Lee, Brian J. Balin, Laszlo Otvos, 1991).
While both Aβ plaques and NFTs likely contribute to neuronal death, Aβ
accumulation as well as plaque formation precedes and may even induce NFT
formation (Götz, Schild, Hoerndli, & Pennanen, 2004). Immunotherapy studies in
mice targeting A and reducing its accumulation also result in a reduction in the
levels of intracellular phosphorylated tau (Frank M LaFerla, 2010). Following
cessation of immunotherapy Aβ pathology reappears before NFTs.
6

Vesicular Accumulation in AD
Abnormal accumulation of vesicles is another well documented
pathological hallmark of AD, as well as many AD models (Nixon, 2006). These
vesicles often express markers of autophagy, endosomal and lysosomal (AEL)
subcellular compartments and may thus be fusions of these ordinary types of
vesicles. Aggregated Aβ is present within AEL vesicles both intracellularly as well
as in extracellular space (Ihara, Morishima-Kawashima, & Nixon, 2012). Neurons
normally experience a high rate of vesicular turnover and the increase in number
as well as size of AEL vesicles in AD or models suggests that their turnover
efficiency is diminished and they are thus dysfunctional (Ling, Magallanes, &
Salvaterra, 2014). Fusion of endosomes or autophagosomes with lysosomes is
considered the end stage leading to vesicular cargo digestion allowing the
digested components to be reused for cellular biosynthetic functions. In AD and
AD models the vesicular fusion pathways apparently still operate normally but the
cargo is no longer being digested thus preventing vesicular turnover.

The Genetics of AD
AD can be divided into two general forms: sporadic (SAD) and familial
(FAD). Like its name suggests, FAD exhibits an autosomal dominant inheritance
pattern as a result of causative mutations in one of three genes present in two or
more generations of relatives (Kovacs & Tanzi, 1998). There are no
distinguishing characteristics of FAD and SAD other than the observation that
FAD patients develop symptoms at a relatively younger age (also known as early
7

onset AD, EOAD). The three genes mutated in FAD are APP, Presenilin 1
(PSEN1), and Presenilin 2 (PSEN2) (Bertram, Lill, & Tanzi, 2010). FAD
mutations in APP can be located within the Aβ1-42 sequence but are usually
located at or very near the cleavage sites of α-secretase or β-secretase (Weggen
& Beher, 2012). Either PSEN1 or PSEN2 forms the active site of a four subunit
protease complex, γ-secretase, necessary for amyloidogenic processing of APP
into Aβ (Zheng & Koo, 2011). All known forms of FAD result in more efficient
production of A1-42 over A1-40 providing the strongest evidence in favor for the
amyloid hypothesis of AD: A1-42 is causative (Selkoe & Hardy, 2016). Additional
evidence comes primarily from transgenic mouse models of AD where agents
known to slow or prevent APP proteolysis into A1-42 (or even remove A1-42
aggregates) generally decrease the severity of AD-like phenotypes in these
models (Vardy, Catto, & Hooper, 2005). Unfortunately, it has not yet been
possible to translate these findings into patient treatments as all clinical trials
based on these mouse models have failed. Recent versions of the amyloid
hypothesis postulate that the production and aggregation of Aβ1-42 may cause
subsequent plaque formation, tau tangle formation, and subsequently
neurodegeneration but the mechanistic details involved are still poorly
understood.
In addition to APP, PSEN1, and PSEN2, genome wide associated studies
in individuals diagnosed with AD have identified several genes associated with a
higher incidence of AD risk (Lambert et al., 2013). The earliest identified and
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quantitatively most important among these is the presence of a risk allele of
apolipoprotein E (APOE) (Kanekiyo, Xu, & Bu, 2014). APOE has three alleles
(ε2, ε3, and ε4). Individuals carrying just one copy of ε4 have up to a four-fold
increase in the likelihood of developing AD and copies correlates with an
increased risk by almost fifteen-fold (Farrer et al., 1997). Interestingly, APOE ε4
carries an increased risk in both FAD and SAD (Liu, Kanekiyo, Xu, & Bu,
2013)(C.-C. Liu et al., 2013). APOE normally functions in cholesterol metabolism.
APOE4 promotes oligomerization of Aβ peptides and is also found in tangles
(Castano et al., 1995). Other studies as well as our own genomic sequencing
data shows the H9 cell line used in our model is heterozygous ε3/ ε4 (Funk et al.,
2012).

Current Models
The most common models of AD are constructed in mice, invertebrates, or
cell lines. The predominant models used for preclinical development of AD
treatments are transgenic mice (Frank M. LaFerla & Green, 2012). Mouse
models have been extremely successful in identifying the proteolytic processing
mechanisms for production of Aβ as well as accumulation of plaques, but they
have been less successful in modeling other types of AD pathology. Most
extensively studied mouse models rely on overexpression of one or more mutant
forms of a human AD causative transgene. Some models even use additional
mutations in other genes not known to be affected in AD to achieve AD-related
phenotypes. Notably, FAD patients have only a single mutation in one of the
9

three causative genes (APP, PSEN1, PSEN1) while SAD cases have no known
cause. It is thus hard to interpret transgenic mouse results with respect to AD.
Perhaps the two biggest phenotypic deficiencies in nearly all mouse
models is the absence of significant neurodegeneration and the lack of tangles
(Alzforum, 2016). More recent mouse models were designed to replace the
endogenous mouse App gene with a copy of a mutant human gene. This
strategy has eliminated potential problems caused by overexpression, but these
animals still require human APP processing using mouse proteins and
neurodegeneration has not been reported (Saito et al., 2014).
Invertebrate models of AD often rely on direct expression of Aβ1-42
transgenes (Gutierrez-Zepeda & Luo, 2004; K Iijima-Ando & Iijima, 2009). This
strategy results in models exhibiting an impressive array of AD-like phenotypes
including selective accumulation of A1-42, chronic age-dependent neurological
deficiencies, and significant neurodegeneration (Cowan, Shepherd, & Mudher,
2010; Kanae Iijima-Ando & Iijima, 2010).
One drawback is that they share an absence of tangle formation just as in
mouse models. Remarkably, a few mouse models have also been examined
using direct expression of A and they share the robust neurodegeneration
phenotypes with invertebrates but are not widely used or no longer available
(Abramowski et al., 2012; LaFerla, Tinkle, Bieberich, Haudenschild, & Jay, 1995;
Lewis et al., 2001). Though animal models have given us a great deal of
knowledge about AD, the species differences between humans and animals are
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increasingly being appreciated and could play a significant role in the limitations
of current AD models.
An obvious way to overcome species differences is to create human
embryonic stem (hES) or induced pluripotent stem (iPS) cell models of AD. Two
general approaches have been used: converting iPSCs from AD patient derived
cells into neurons or genomic editing to introduce AD mutations into hES or iPS
cells. The first strategy has been used by several groups with promising results
(Kondo et al., 2013; Yagi et al., 2011; Yang, Li, He, Cheng, & Le, 2016).
One drawback of iPSC studies is the absence of a proper control cell line.
Age matched non-AD cells have been used but these are likely to have a host of
genetic variants that may complicate simple direct interpretations of AD-like
phenotypes. This can be avoided by using genetic editing technologies.
However, it is still difficult to imagine how cell models can be experimentally
analyzed long enough to view age-dependent changes. Most stem cell culture
experiments last for a few months at the most and AD takes decades to develop
in humans (McGowan, Eriksen, & Hutton, 2006). Some progress has be made in
solving these aging problems, primarily by stressing the cells or incorporating
expression of genes with accelerated aging phenotype (Studer, Vera, &
Cornacchia, 2015). My model has taken a different approach. First, genetic
variance is limited by using a standard well characterized human embryonic stem
cell as a starting point. Second, my cells have been genomically edited to directly
express a secretory form of A thus avoiding the time it would take to
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proteolytically process APP peptide. This strategy also allows phenotypic
characterization of A1-42 and A1-40 separately, something impossible to do in
APP models. A1-40 which is largely non-toxic in invertebrate direct expression
models and less toxic in mouse direct expression models. The A1-42 edited cell
lines I observed thus have the potential to serve as an editing control. While not
specifically a model of AD per se, we hypothesize that this system of isogenic
lines will represent a new tool that can be used to understand the consequences
of A1-42 accumulation that result in AD-like neurodegeneration. The final feature
of these cells is that the edits are incorporated into the App gene itself and is thus
not an overexpression model but rather relies on expression control from the
normal App regulatory elements.

Constructing a New Human ES Cell Based Model
All cell lines used in this study were derived from the well-defined and
established WA09 hESC line (referred to herein as H9). Multiple independently
isolated clones were established following transcription activator-like effector
nuclease (TALEN) genomic editing. We targeted a sequence in the first exon
upstream of the translation initiation site in App by designing TALEN pairs that
introduce a double strand break (DSB). The DSB was repaired in the presence of
a plasmid containing a cassette constructed of a left and right homology arm
(flanking the targeted cutting site), a secretory signal sequence (from the R.rattus
preproenkephin gene), either an Aβ1-40 or A1-42 coding sequence followed by a
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drug selection gene and a polyA tail using normal homology directed repair. This
resulted in a secretory form of either A1-42 or A1-40 peptide under the control of
the normal App promoter. The secretory signal directs expression routing through
the normal secretory pathway as known for APP and the secretory signal is
completely removed during normal secretory processing. Multiple independently
isolated clones were obtained and examined for each edit ensuring that results
are genotype specific and not likely a result of unknown modifications during
editing. PCR analysis and direct sequencing of the editing junctions confirmed all
edited cells. Expression of the edited genes can be specifically monitored by
qRT-PCR using a forward primer in the rat secretory sequence that is not present
in the human genome. Details of sequences and methods used to construct this
model can be found in Appendix A.
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CHAPTER TWO
NEURONAL DEVELOPMENT

App and Aβ Insert Expression
It is important to first establish the level of mRNA in edited samples for
both the edit itself as well as the remaining unmodified App allele. While the
exact function of APP is not known, a few reports have claimed a role in early
development. I therefore measured both Aβ expression and App expression
using qRT-PCR throughout development. There is a significant decrease in both
Aβ1-40 and Aβ1-42 mRNA comparing stem cells to embryoid bodies (Figure 2).
The pattern and extent of decrease appears similar for each edit. Following
dissociation of EBs and differentiation into neurons there is a large increase in A
expression and the pattern is similar for each edit, however, A1-40 appears to
express more peptide mRNA (Figure 2).
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Figure 2. Expression of Aβ1-40/42 Inserts at Different
Developmental Stages.
Expression of Aβ inserts was measured by qRT-PCR
using primers in the secretory signal sequence which
cannot be found in the human genome. In both cell
lines, expression decreases from stem cells to neurons
by ~24-fold. In Aβ1-40, expression from EB to neurons
increased by ~308-fold. Expression in Aβ1-42 from EB to
neurons increased by ~107-fold. Overall, both
genotypes increase expression of the Aβ insert from SC
to neuron by ~14-fold.

App expression also showed a similar pattern comparing Aβ1-40 and Aβ1-42
NCs. As expected, expression of App in edited lines was approximately half the
expression relative to unedited H9 cells (Figure 3). Somewhat unexpectedly,
expression of the Aβ edited mRNA was ~37-fold less than App in edited
genotypes relative to the unedited H9 cell line (Figure 3). This may potentially be
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explained by functional disruption of an App enhancer sequence reported within
the first intron of the gene as a result of cassette insertion in this region (Shakes
et al., 2012). This reduced expression may in fact be beneficial since Aβ1-42
peptide has acute proteotoxic properties and lower expression may allow
development of more chronic toxicity as the peptide slowly accumulates as the
neurons age, a situation similar to AD. In any case, the A mRNA levels are
indistinguishable from background in unedited cells.

Figure 3. Expression of App and Aβ in Neurons of
All Three Genotypes.
App expression in my Aβ1-42 and Aβ1-40 neurons is
near half the expression of H9 neurons and not
significantly different from each other. Expression of
the Aβ1-40 and Aβ1-42 inserts are both 37-fold less
than their respective App expressions.
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Alzheimer’s is Not a Developmental Disease
AD is not considered a developmental condition but rather a phenotype of
old age. Before evaluation of direct A-dependent phenotypes in my cell lines it
is crucial to first determine if they can differentiate normally. After EB
dissociation, neurons begin to migrate into organized neuronal clusters (NC).
These clusters grow larger as a function of culture time and eventually develop
extensive neuronal processes and form synaptic connections within a particular
cluster and apparently with adjacent NCs. Upon visual inspection using Hoffman
differential interference microscopy, the neurons and NCs of unedited or either
edited genotype appear similar in morphology and increase in size as they age
(Figure 4). I compared the average area of NCs among all three genotypes at 615 days, 16-25 days, and 26-35 days. Data were collected across independent
differentiations to control for normal variability in culture morphologies. The
average area of NCs appeared to increase. Statistical analysis of pooled data
from multiple differentiations (ANOVA corrected for multiple comparisons using
Dunnett’s method), however, failed to reach significance. There can be several
potential technical reasons for this statistical anomaly. For example, it may have
been better to measure volumes of NCs rather than area. The most likely reason,
however, is that within a particular neuronal differentiation the increase in NC
size is obvious but when pooling data form different individual neuronal
differentiations the variations are greater than the increase in NC area. Ideally,
this possibility could be tested by increasing the number of individual neuronal
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differentiations however this was not possible due to time and expense
considerations. The source of variation in stem cell differentiation is a well-known
problem in stem cell biology of unknown cause.
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Figure 4. Neuronal Clusters Appear Similar and Grow Larger As They Age.
The appearance of the NCs of all three genotypes is similar up to 34 days and
grow slightly larger as they age (top). The sizes of neuronal clusters at
different age ranges were measured by manually tracing around the
boundaries and measuring the area of several clusters within each culture.
When the average areas are compared at each age range using ANOVA (with
Dunnett’s multiple comparisons) there was no statistically significant
difference.
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To determine if the edits made to my cells affected the number of neurons
that ultimately develop, I immunocytochemically stained and imaged 10 day old
neurons AED (after embryoid body dissociation) for two neuron specific markers
that are localized within two different cellular compartments. The first, NeuN, is a
nuclear neuronal marker and the second, doublecortin (DCX), is a cytoplasmic
neuronal marker. The neurons of all three genotypes at 10 days AED appear so
similar in number and morphology that it is difficult to distinguish them (Figure 5).
When the percentage of positive staining cells is compared among H9, Aβ1-40,
and Aβ1-42 following image analysis, I find that there is no statistical difference for
NeuN positive or DCX positive cells (Figure 5).
Taken together, the results in this section suggest that all 3 genotypes
analyzed can develop and differentiate normally (i.e. similar to the H9 parental
genotype) and thus phenotypic analyses at later stages may be confidently
predicted to be a result of edited peptide expression rather than effects on earlier
developmental processes.
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Figure 5. Edits Do Not Affect the Number of Neurons That Develop After
Differentiation.
Neurons were immunocytochemically stained for two neuronal markers,
doublecortin (DCX) and NeuN 10 days AED. The number of cells positive for
each type of neuronal marker were counted in several fields and the
percentages of positive cells were compared. There was no difference by
visual comparison in morphology and number (top) as well as by statistical
analysis (bottom, ANOVA with Dunnett’s multiple comparisons test, N=15-38).
Scale bar 30µm.
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CHAPTER THREE
ALZHEIMER’S-LIKE PHENOTYPES

Aβ Aggregation
An early hallmark of AD is aggregation and accumulation of the Aβ1-42
peptide and thus measuring the aggregation of Aβ is a logical first step in
examining differentiated neurons in my cultures. Aβ aggregation was measured
immunocytochemically by staining 32-34 day old (AED) cultures with an antibody
specific for the aggregated form of Aβ (7A1a) (Figure 6). Upon visual inspection,
aggregated Aβ appears to be more abundant in Aβ1-42 NCs relative to A1-40.
Quantification of the area of 7A1a staining, normalized to the area of neuronal
marker Tuj1 to control for neuronal number indicates that Aβ1-42 NCs contain
about 4.8 times more aggregated Aβ peptide when compared to unedited H9
NCs and about 1.8 times more than Aβ1-40 NCs (Figure 6). Statistical analysis of
the average of 7A1a area in NCs of each genotype reveals that the increased
aggregation of Aβ is statistically significant (H9 vs Aβ1-42 P=0.0001 and Aβ1-40 vs
Aβ1-42 P=0.0422). In addition to having increased Aβ aggregation, the aggregated
Aβ also appears to localize near fragmented nuclei with especially bright
fluorescence (Figure 7).
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Figure 6. Aβ Aggregation in Neuronal Clusters 32 Days AED.
NCs were immunocytochemically stained with an antibody specific for
aggregated Aβ (7A1a). Upon visual comparison, Aβ1-42 NCs clearly contain
significantly more aggregated Aβ1-42 than either H9 or Aβ1-40 (top). When
these images are quantified and normalized to the amount of Tuj1 present (a
neuronal marker), Aβ1-42 NCs contain 54%, Aβ1-40 30%, and finally H9 NCs
average 11%. Statistical analysis of average percentages of 7A1a shows a
significant difference between H9 and Aβ1-42 (P=0.0001) and H9 vs Aβ1-40
(P=0.0422). Scale bar 10µm.
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Figure 7. Aβ Aggregation is Localized Near Fractured Nuclei.
7A1a staining at 34 days AED shows that aggregated Aβ is heavily localized
around fractured nuclei (arrows, right image) and the nuclei of neurons with
very little staining (arrow heads, right image) do not have this fractured
appearance. The live/dead assays at 34 days AED show that these neurons
with fragmented nuclei are likely to be dead and/or dying (left image, arrows).
Scale bars 10µm.

Synapse Decrease
A decrease in synapses is an early stage cellular phenotype which has
been well documented in AD and thought to be associated with mild cognitive
deficits that appear in individuals long before more severe symptoms. I used
immunocytochemistry to measure synapsin1 puncta as an index of synapses.
Synapsin1 stains a protein present in synaptic vesicles. Individual vesicles are
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below the resolution limit of light microscopy, but cluster in groups at neuronal
synapses. Image analysis revealed a statistically significant 2.8-fold decrease in
the number synapses present in Aβ1-42 neurons compared to H9 neurons (Figure
8).

Figure 8. Aβ1-42 Neurons Have Significantly Decreased Synapsin1 Puncta.
Left, MIP of 0.5µm sections taken of H9 and Aβ1-42 NCs. H9 NCs averaged
27.3 synapsin1 maxima/nucleus and Aβ1-42 NCs 9.9 maxima/nucleus
(P=0.0203). Scale bar 20µm.
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Neurodegeneration
The later stages of AD are marked with increasing neuronal death in
affected brain regions. A live/dead assay was used to estimate this phenotype in
cultured cells at 10, 34, or 70 days AED (Figure 9). The method uses two
fluorescent dyes to distinguish between live and dead cells: ethidium homodimer
and calcein AM and is performed by incubating live neuronal cultures with a
mixture of the indicators. Calcein AM is readily taken up by live cells but only
fluoresces green when cleaved by cellular esterases which are not present in
dead cells. Ethidium homodimer is live cell membrane impermeable but will
fluoresce red when bound to DNA in dead cells with compromised
plasma/nuclear membranes. At 34 days AED, there is no significant difference in
cell death among the three genotypes. When the live/dead assay is repeated at
70 days AED, there is a large increase in cell death for both Aβ1-40 and Aβ1-42
genotypes relative to H9 parental cells (Figure 9). There is 2.3 times more cell
death in Aβ1-42 NCs over H9 and about 2 times more death in Aβ1-40 NCs. To my
knowledge this is the first mammalian experimental model that clearly exhibits a
chronic progressive Adependent neurodegeneration phenotype and could thus
be used to understand the mechanism of this process in human neurons.
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Figure 9. Neuron Survival at 34 and 70 Days AED.
A live/dead assay using calcein AM and ethidium homodimer was done on
neurons at 34 days and 70 days AED. At 70 days AED Aβ 1-42 NCs begin to
take on a granulated appearance and the number of axonal projections is
reduced (left, brightfield images). Neuron death was quantified by calculating
the percentage of red (dead) area of each NC. There is no difference in cell
death between genotypes at 34 days AED. At 70 days AED, H9 NCs average
16%, Aβ1-40 33%, and Aβ1-42 38% red area. ANOVA with Dunnett’s multiple
comparisons test reveals that the increase in cell death is significant (H9 vs
Aβ1-40 P=0.0019 and H9 vs Aβ1-42 P=0.0001, N=7-92). Scale bar 50µm.
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Changes in Gene Expression and Pathway Analysis
Since my cells are isogenic, except for the edited alleles, they may be a
good system to analyze the changes in gene expression that are dependent on
direct expression of A1-42 or A1-42. mRNA was isolated from 34 day old neurons
from multiple independently isolated clones of each genotype and characterized
using RNA sequencing analysis. This provides data for the whole transcriptome
rather than focusing on a preconceived hypothesized gene as is common in PCR
based analyses. The differential gene expression (i.e. comparisons among
samples with different genotypes) can provide unbiased clues to genes and
pathways that are perturbed because of peptide expression and identify specific
genes that could be targeted for therapeutic development and mechanistic
analysis.
Clustering of expression changes in multiple samples of different
genotypes shows that Aβ1-42 clones group together and therefore have a similar
expression pattern (Figure 10). Clustering of Aβ1-40 and H9 genotypes are
interspersed suggesting that they have more similar expression patterns to each
other than to the A1-42 samples (Figure 10).
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Figure 10. Heatmap of Changes in Gene Expression.
Gene expression of 34 day AED neurons was centered
on the median per batch prior to clustering. Results
indicate that quantitative gene expression determined by
RNA-seq analysis groups the A1-42 samples together
(i.e. they are similar to each other, relative to the A1-40
or H9 genotypes). Note also that independently isolated
clones cluster together. The data for H9 and A1-40
indicates that individual samples are interspersed with
each other with respect to gene expression. This is
consistent with A1-42 having different phenotypes
relative to either A1-40 or H9.

Specific differentially expressed genes can be identified by plotting their
expression p-values against their fold change. This results in a volcano plot
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(when using the negative log of the p-values) allowing genes of high probability
and high magnitude of change (either up or down regulated) to be easily
visualized (Figure 11). When the top genes with changes in expression of both
Aβ1-40 vs H9 and Aβ1-42 vs H9 are plotted together, there are some changes in
expression that appear in both genotypes (Figure 12). This suggests that some
differentially expressed genes in my edited cells (compared to unedited cells)
may be due to the editing of one App allele rather than the expression of A
peptide. Changes seen in Aβ1-42 but not in Aβ1-40 are most likely to be Aβ1-42
specific.
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Figure 11. Volcano Plots of Differentially Expressed Genes at 34 Days
AED.
Fold changes in gene expression were plotted as a function of their log(p-value) (i.e. the absolute value of their significance). Only
expression changes 2 > 𝐹𝐶 < −2 and p<0.00001 are labeled in red (up
regulated) or blue (down regulated.
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Figure 12. Some Changes in Expression Are Likely Due to App Editing.
The highest upregulated (top) and downregulated (bottom) genes of Aβ 1-40 vs
H9 and Aβ1-42 vs H9 at 34 days AED. Some changes in expression occur in
both the Aβ1-40 and Aβ1-42 genotypes and may thus be due to editing of one
App allele (highlighted in grey). Changes in expression that do not appear in
Aβ1-40 are most likely to be Aβ1-42 dependent (highlighted in red).
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Figure 13. IPA Analysis of RNA Sequencing Data.
Ingenuity Pathway Analysis software was used to predict disease and
function changes associated with differential gene expression of A1-42
compared to H9. The two categories with the highest z-score were
memory (z=-1.980) and neuronal cell death (z=1.658) and are depicted.
Genes that are upregulated appear in shades of red and
downregulated genes appear in green with the darker shades indicating
a higher fold change in expression. The memory pathway appears in
blue, indicating that the expression profile of Aβ1-42 neurons is likely to
be inhibiting memory function. Neuronal cell death appears in orange,
indicating that neuronal cell death pathways are likely to be activated.
Remarkably, both of these phenotypes are key features of AD.
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I also performed pathway analysis using Ingenuity software, a server
based biological ontology. Remarkably the A1-42 vs H9 differential gene
expression comparison revealed the two highest scoring (z-score, statistically
normalized fold changes) for two functional/disease pathways: memory and
neuronal cell death. These are the likely first and later stage phenotypes of AD.
Figure 13 shows the pathways in a network diagram where individual genes are
color coded relative to their differential expression and the arrows indicate
predicted increases or decreases in the function/disease. In addition to these two
pathways, there is also differential expression in several other genes associated
with other pathways relevant to AD (Figure 14).
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Figure 14. Differentially Expressed Genes Relevant to AD.
RNA sequencing data of Aβ1-42 vs H9 differential expression of genes at 34
days AED related to AD. The shapes of differentially expressed genes
correspond to their known functions and the darker shades correspond to
higher fold changes. Under each gene is the fold-change found in RNA
sequencing data. Pathways listed at the bottom are all AD related and are
associated with changes in the genes listed. The Aβ1-42 genotype shows
expression changes of several genes in pathways related to AD.
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CHAPTER FOUR
SUMMARY AND DISCUSSION
The genomic editing of my hESCs did not affect their ability to successfully
differentiate into neurons. I measured the number of neurons present shortly
after differentiation and found no difference between edited and unedited cell
lines. After finding no differences in the number of neurons that develop, I
followed and measured them as they aged. Up to 34 days, NCs appear similar in
morphology and size. This was supported by the fact that when their area is
measured, they are similar in size and increase similarly in size as they age.
Aβ1-42 neurons have fewer synapsin1 puncta 32 days AED. Decreases in
synapsin1 vesicles is an early and well-known cellular phenotype of AD. A
decrease in the presence of synapsin1 has been previously shown to also
coincide with dysfunction in the synaptic vesicle recycling pathway (Bogen et al.,
2006).
The neurons in the Aβ1-42 line accumulate significantly more aggregated
Aβ than either H9 or Aβ1-40 34 days AED. Aβ1-42 and Aβ1-40 neurons also
experience nearly triple the amount of cell death as H9 70 days AED. This is
consistent with the fact that AD is a chronic and progressive disease. The Aβ1-42
neurons accumulate aggregated Aβ long before neuronal death begins in the
same way that amyloid plaques appear decades before symptoms in AD
patients. This is also supportive of the hypothesis that Aβ is causative in AD.
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There is much debate as to whether intracellular or extracellular
aggregation of Aβ is toxic to neurons. Immunocytochemical staining of my Aβ1-42
neurons supports the intracellular hypothesis. Because of the nature of cell
culture, medium is replaced often and culture in 2D likely prevents Aβ from
accumulating outside of neurons. In addition to this, immunocytochemical
staining with 7A1a antibodies shows that aggregated Aβ accumulation is mainly
located near fractured nuclei. From my live/dead assays, I also know that these
cells are dead and/or dying.
RNA sequencing data of my neurons shows that independently isolated
clones of each genotype cluster together and provides evidence that the
phenotypes I see are not clone specific. There is also differential expression in
several genes in pathways that are associated with AD, the most prominent of
these being memory and neuronal cell death. When the most highly differentially
expressed genes of Aβ1-40 vs H9 and Aβ1-42 vs H9 are compared, there is some
overlap. These overlaps suggest that there may be some changes related to the
editing of App.
This cellular model has advantages over other models in that it has direct
expression so the time and uncertainty of factors required to generate Aβ1-42 from
APP are bypassed. Direct expression also eliminates the decades that is usually
required for APP to be produced and accumulate within the brain, making this
model suitable for a laboratory timescale. Since these cells are also isogenic the
results obtained from this model are not confounded by the genetic variation that
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often plagues iPSC and mouse models. This is supported by the fact that
multiple independently isolated clones of each genotype show very limited
differences. These cells are also heterozygous for ε4, an at-risk allele for AD.
One disadvantage of this model is that it requires a reliable neuronal
differentiation protocol. There is variation in the differentiation of these cells and I
have found that during differentiation there is sometimes a non-genotype specific
failure of cells to survive the process. Other members of the lab also experience
this non-genotype specific survival failure. Another potential drawback of this
model is that there are solely neurons present in these cultures. Thus, it cannot
address interactions with or issues related to the blood brain barrier as well as
contributions by astrocytes or microglia.
While current and past models have provided researchers with answers
about where Aβ comes from, how Aβ is processed from APP, and how Aβ
aggregates, we still do not understand the mechanism behind how the neurons
of AD affected patients are dying. Part of the reason for this is the lack of a model
for AD that presents with clear AD phenotypes, namely neurodegeneration, as
well as possible species differences between animal models and humans. This
newly created model focuses on Aβ1-42 dependent phenotypes and addresses
both concerns by utilization of hESCs with direct expression of Aβ1-42. By directly
expressing Aβ1-42 in human cells, this model also eliminates the time and
uncertainty of factors required to generate Aβ1-42 from APP as well as the
decades that it usually takes to accumulate Aβ. I have demonstrated that these
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edited stem cells can successfully differentiate into neurons without any
significant abnormalities and later develop many of the characteristic
neuropathologies of AD in culture. This is the first known model of Aβ1-42
dependent ND in human neurons and could thus be used to identify therapeutic
agents that slow or prevent this process and in addition may help elucidate the
possible mechanisms behind neuronal death in AD.
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CHAPTER FIVE
MATERIALS AND METHODS

Cell Culture and Maintenance
Cell Lines
WA09 H9 human embryonic stem cells were obtained from the WiCell Research
Institute (Madison, WI, USA). TALEN editing was used to insert Aβ1-42 or Aβ1-40
sequence in the first exon of one APP allele. Cassette sequences can be found
in Appendix A.
Stem Cell Maintenance
Stem cells were maintained on DR4 IRR mouse embryonic fibroblasts
(MTI Global Stem; Gaithersburg, MD, USA) in HuES medium. HuES medium is
Dulbecco’s Modified Eagles Medium: nutrient mixture F-12 (DMEM/F12: Gibco),
20% KnockOutTM Serum Replacement (Invitrogen), 50 U Penicillin and 50 mg/mL
Streptomycin (Penicillin-Streptomycin, Gibco), 1% MEM Non-essential Amino
Acids (Gibco), 1mM GlutaMax (Gibco), 0.1 mM β-Mercaptoethanol (Sigma), and
20ng/mL basic fibroblast growth factor (bFGF; Stemgent).
Neuronal Differentiation
Cells were differentiated according to a modified protocol based on a previously
established protocol (Amoroso et al., 2013).
Embryoid body generation: On day zero, confluent wells of stem cells were
passaged by incubation with Dispase (1mg/mL, Stem Cell Technologies) for 1015 minutes. Cells were then washed twice with DPBS and triturated in 1mL of
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PBS. Cells were then resuspended to 4x105 cells/mL in HuES supplemented with
10µM Y-27632 (StemGent), 10µM SB-431542 (StemGent), 0.2µM LDN-193189
(StemGent) and plated in 10cm petri dishes coated with 6mL of 1.5% Agar (or
ultra-low attachment dishes). Day two: Embryoid Bodies were collected into
50mL conical tubes, allowed to settle for 45 minutes, and as much media was
removed from the cells before plating again in the same media as day zero. Day
three: Collect embryoid bodies as on day two and change to Neural Induction
Medium (NIM) supplemented with 20ng/mL bFGF, 10µM Y-27632, 10µM SB431542, and 0.2µM LDN-193189. NIM is DMEM/F12, 50U Penicillin, 50mg/mL
streptomycin, 1% Non-essential Amino Acids, 1mM Glutamax, 1x N-2
Supplement (Gibco), and 2µg/mL Heparin (Sigma-Aldrich). Day five: Collect cells
as above and switch to NIM with 20ng/mL bFGF, 10µM SB-431542, 0.2µM LDN193189, 10ng/mL brain-derived neurotrophic factor (BDNF, PreproTech),
0.4µg/mL Ascorbic Acid (AA, Sigma), 1µM Retinoic Acid (RA, Sigma). Day 7-15:
Collect cells as above and use NIM supplemented with 10ng/mL BDNF,
0.4µg/mL AA, 1µM RA, 2µM Smoothened agonist (SAG, Calibochem). Change
media every 2-3 days. Day 17+: Collect cells as above and switch to Neural
Differentiation Medium (NDM) supplemented with 10ng/mL BDNF, 0.4µg/mL AA,
1µg/mL RA, 2µg/mL SAG, 1x B-27 supplement (Gibco), 10ng/mL glial cell linederived neurotrophic factor (GDNF, PreproTech), 10ng/mL ciliary neurotrophic
factor (CNTF, PreproTech), 10ng/mL insulin-like growth factor 1 (IGF-1,
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PreproTech). Change media every 2-3 days. Dissociate EB bodies anytime
between days 24 through 28.
Embryoid body dissociation: EBs are collected and rinsed in calcium and
magnesium-free PBS (Corning Cell Grow). Then they were incubated with trypsin
for 1-4 minutes. Then one equal volume fetal bovine serum (FBS, Hyclone) and
two volumes of complete trituration wash medium (CTWM) are added. CTWM
consists of calcium and magnesium free PBS, 25mM glucose (Mallinchrodt),
0.1% dialyzed bovine serum albumin (BSA, Roche), 1x N-2 supplement, 1x B-27
supplement, 2mM MgCl2, 1mM ethylenediaminetetraacetic acid (EDTA, J.T.
Baker), and 2.5% FBS. Centrifuge cells at 1400rpm for three minutes. Remove
supernatant and re-suspend in 1mL of CTWM. Then triturate clumps with a
p1000 pipette for seven passes. Add 10-12mL of CTWM and filter through a
40µm filter (Corning). Record volume and count cells. Centrifuge at 1400rpm for
4 minutes and resuspend cells in NDM supplemented with 1x B-27 supplement,
10ng/mL BDNF, 10ng/mL GDNF, 10ng/mL IGF-1, 10ng/mL CNTF, 0.4µg/mL AA,
25µM glutamate, 25µM β-mercaptoethanol, and 1mM RA. Seed cells at 1.5 1.8x106 cells per well of a 6-well plate coated with laminin (company) and polyornithine (company). Laminin in DMEM/F12 (15µg/mL) is coated 48 hours prior to
cell plating for 24 hours and poly-ornithine in DMEM/F12 (100µg/mL) is coated
after for 24 hours prior to cell plating.
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Neuron Maintenance
Neurons were maintained in NDM supplemented with 1x B-27 supplement,
10ng/mL BDNF, 10ng/mL GDNF, 10ng/mL IGF-1, 10ng/mL CNTF, 0.4µg/mL AA,
25µM glutamate, 25µM β-mercaptoethanol, and 1mM RA. Cultures were treated
with 0.5µM ethynyl deoxyuridine (EdU) for 24 hours once a week, starting on the
day of dissociation until day 50 post EB dissociation to maintain post-mitotic
neurons only.

Quantitative Real-Time PCR
Total RNA extraction was done using RNeasy Micro Kit from (Qiagen)
using the manufacturer’s protocol. One well of a 6-well plate of healthy neurons
usually yields approximately 1x106 cells and 1-3µg of total RNA. RNA
concentration and purity were determined using a NanoDrop ND-1000
Nanospectrophotometer (ThermoFisher Scientific). cDNA was prepared using
qScript cDNA SuperMix (Quanta) following the manufacturers protocol. All qRTPCR reactions were carried out in a 20µl reaction mixture containing 12.5µl iQTM
SYBR® Green Supermix (Bio-Rad), 2µM of each forward and reverse primer,
0.25µg cDNA, and DEPC-Treated Water (Ambion) to adjust the final volume to
20µL. Amplification was carried out using a BioRad CFX96 TouchTM Real-Time
PCR Detection System in clear 96 well sealed plates.
Cycling Conditions were as follows:
Initial denaturation/enzyme activation 95°C for 3 minutes
Denature: 95°C for 30 seconds
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Annealing and Extension: 55°C for 20 seconds, 40 cycles
Melt Curve: 55°C to 95°C for 5 seconds in 0.5°C increments

Table 1. Quantitative Real-Time PCR Primers
Primer
APP5*
GAPDH
Aβ†

Forward (5’→3’)
GAGGAGGATGACTCGGATGTCTGG
ATGGGGAAGGTGAAGGTCGGAGTC
ATGGCGCAGTTCCTGAGA

Reverse (5’→3’)
GGTGGTTCTCTCTGTGGCTTCTTCGT
GGGATTTCCATTGATGACAAGCTTCCCG
ATGATTGCACCTTTGTTTGAACC

*App5 primer spans the junction between exons 5 and 6
† primer is the beginning of the secretory signal sequence (not found in the human genome)

Immunocytochemistry
Cells were grown on 15mm No.1 coverslips (FisherScientific) and
incubated with freshly made 4% Paraformaldehyde for 20 minutes. Then, 4%
Paraformaldehyde is removed and cells are washed with PBS for 5 minutes 3x.
Coverslips were stored in 0.03%NaN3 PBS at 4°C until use.
For Immunostaining, coverslips were incubated with blocking buffer (0.3%
Triton X-100 and 5% Bovine Serum Albumin in PBS) for 45 minutes at room
temperature. Blocking buffer is then removed, coverslips are briefly rinsed with
PBS, and primary antibodies diluted in antibody buffer (0.3% Triton x-100 and
1% Bovine Serum Albumin in PBS) are added. Cells are incubated in primary
antibodies overnight at 4°C. Primary antibodies are then removed and coverslips
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are washed with PBS for 5 minutes 3x. Secondary antibodies are diluted with
antibody buffer and are then added to the coverslips and incubated for two hours
at room temperature protected from light. The secondary antibody solution is
then removed and coverslips are washed again with PBS for 5 minutes 3x.
Coverslips are then incubated with DAPI (1µg/µl) for 5 minutes at room
temperature protected from light and washed with PBS for 5 minutes 2x.
Coverslips were then mounted onto glass slides using Dako Fluorescent
Mounting Medium. Fluorescent images were taken using the Zeiss Observer II
microscope using either of the following objectives: 63X/1.4NA Plan-Apochromat
DIC OIL or 20X/0.80NA Plan-Apochromat DIC and a Zeiss AxioCam 506. ZEN
Blue software was used to capture images.

Table 2. Antibodies Used for Immunocytochemistry
Antibody
NeuN
Lamp1
DCX
Oligomeric Aβ (7A1a)
Synapsin I

Dilution
2µg/mL
0.25µg/mL
1µg/mL
1.4µg/mL
0.2µg/mL

Supplier
Abcam
Abcam
Abcam
New England Rare Reagents
Abcam

Catalog No.
Ab104224
Ab24170
Ab77450
N/A
Ab8

Goat anti-Chicken IgY H&L
(Alexa Flour 488)

3.9-3.98µg/mL

Abcam

Ab150169

Goat anti-Rabbit IgG H&L
(Alexa Flour 488)

2µg/mL

Abcam

Ab150077

Goat anti-Mouse IgG H&L
(Alexa Flour 594)

2µg/mL

Invitrogen

A11005
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Image Analysis
All image handling and processing was done with Fiji image analysis
software (Schindelin et al., 2012). NeuN and DCX positive cells were counted
and normalized to the total number of DAPI stained nuclei present in the same
field. NeuN and DAPI were both counted using the Otsu method in ImageJ and
DCX positive cells were counted manually. Oligomeric Aβ (7A1a) quantification
was done by creating a tightly bound box around each individual neuronal cluster
and cropping the image to this area. Background was subtracted using a 150pixel rolling ball radius. A maximum intensity projection was then created from an
image stack (0.5m Z intervals, 16-60 images), then using the Z-projection
maximum intensity algorithm. The individual color channels were separated and
the Aβ channel was thresholded using the IsoData method to measure the area
of positive staining within the neural cluster and expressed as a percentage of
the total cluster area. Neuronal cluster area was measured from Hoffman
interference contrast images by using the freehand tool to manually trace the
edges of clusters and using the measure area function.
Live/dead analysis was done by staining neuronal clusters growing on
coverslips or in 12 well plates using ethidium homodimer (red fluorescence, dead
cells) and calcein AM esterase substrate (green fluorescence when hydrolyzed).
Three to five individual focal planes were obtained as well as a reference
Hoffman interference contrast image. The number of pixels in an area was
measured by separating individual color channels of the stack, subtracting
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background using a 50-pixel rolling ball radius and creating a maximum intensity
projection using auto brightness and contrast to threshold each channel. Data is
presented as percent red area relative to the total area of red plus green
channels.
Synapsin1 puncta quantification was done by subtracting the background
using a 150-pixel rolling ball radius and creating a maximum intensity projection
of a stack of images (0.5µm sections, 11-31 images). The nuclei were counted
the same way as in the DCX and NeuN analysis and the synpasin1 puncta were
counted using the ImageJ find maxima function. The number of synapsin1
puncta were then normalized to the number of DAPI nuclei present in each NC.

Brightfield Imaging
Brightfield Hoffman Modulated Contrast (HMC) images were taken using a
Nikon Diaphot microscope using either of the following objectives: HMC EF 10X
0.25NA 160/- or HMC 20X LWD 0.4NA 160/0-2. A SPOT RT230 camera and
SPOT Advanced software was used to capture images.

Statistical Analysis
All statistical analyses were done using at least three biological replicates
and more than one clone per edited genotype. Each differentiation from stem cell
expansion to neuron is considered one biological replicate. GraphPad Prism 7
software was used for all statistical calculations.
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APPENDIX A
INSERTED CASSETTE SEQUENCES USING TALEN
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Creation of the cell lines used in this research were carried out previously
by members of the Salvaterra lab using TALEN. The sequences of the inserts
include an ATG start codon followed by the rat preproenkephin sequence, the
Aβ1-40 or Aβ1-42 sequence ending with a stop codon, followed by a pgk promoter
with a puromycin selection gene and polyA tail all inserted within the first exon of
App (Figure 15).

Diagram of edited App locus
The inserted cassette is within the first exon of App. The Cassette contains a start
codon followed by a secretory sequence, the Aβ1-42/40 sequence, puromycin selection,
and finally a polyA tail.

APP exon 1, bases in red were cut out by TALENs:
GGATCAGCTG
TCGGCAGCGG
CGGTGGCGGC
GTGCCCCGCG
CGGCTCGGGC

ACTCGCCTGG
TAGGCGAGAG
GCGGGCAGAG
CAGGGTCGCG
GCTGGAG

CTCTGAGCCC
CACGCGGAGG
CAAGGACGCG
ATGCTGCCCG

CGCCGCCGCG
AGCGTGCGCG
GCGGATCCCA
GTTTGGCACT
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CTCGGGCTCC
GGGGCCCCGG
CTCGCACAGC
GCTCCTGCTG

GTCAGTTTCC
GAGACGGCGG
AGCGCACTCG
GCCGCCTGGA

Aβ1-42 insert:
ATGGCGCAGT
ACAGTGCAGG
TTGGTGTTCT
GGCGGTGTTG

TCCTGAGACT TTGCATCTGG CTCGTAGCGC TTGGGTCCTG CCTCCTGGCT
CAGATGCAGA ATTCCGACAT GACTCAGGAT ATGAAGTTCA TCATCAAAAA
TTGCAGAAGA TGTGGGTTCA AACAAAGGTG CAATCATTGG ACTCATGGTG
TCATAGCGTAG

Aβ1-40 insert:
ATGGCGCAGT
ACAGTGCAGG
TTGGTGTTCT
GGCGGTGTTG

TCCTGAGACT TTGCATCTGG CTCGTAGCGC TTGGGTCCTG CCTCCTGGCT
CAGATGCAGA ATTCCGACAT GACTCAGGAT ATGAAGTTCA TCATCAAAAA
TTGCAGAAGA TGTGGGTTCA AACAAAGGTG CAATCATTGG ACTCATGGTG
TCTAG

Pgk promoter with puro selection gene and poly A tail:
ATTCTACCGG
CCCGCTGGGC
CGGTAGGCGC
CCTAGTCAGG
AGTAGCACGT
AGGCCTTTGG
GGGAAGGGGT
AAGGTCCTCC
CTCCTCTTCC
AAGCCCACGG
GCCGCGTTCG
CGGGTCACCG
TGGGTCGCGG
GGGGCGGTGT
GCGCAGCAAC
CTGGCCACCG
CTCCCCGGAG
CCCCGCAACC
CCCGAAGGAC
ATTCACTCCT
GGCTCACAAA
GCCCCTTGAG
TTGGAATTTT
TCAGAATGAG

GTAGGGGAGG
ACTTGGCGCT
CAACCGGCTC
AAGTTCCCCC
CTCACTAGTC
GGCAGCGGCC
GGGTCCGGGG
GGAGGCCCGG
TCATCTCCGG
TGCGCCTCGC
CCGACTACCC
AGCTGCAAGA
ACGACGGCGC
TCGCCGAGAT
AGATGGAAGG
TCGGCGTCTC
TGGAGGCGGC
TCCCCTTCTA
CGCGCACCTG
CAGGTGCAGG
TACCACTGAG
CATCTGACTT
TTGTGTCTCT
TATTTGGTTT

CGCTTTTCCC
ACACAAGTGG
CGTTCTTTGG
CCGCCCCGCA
TCGTGCAGAT
AATAGCAGCT
GCGGGCTCAG
CATTCTGCAC
GCCTTTCGAC
CACCCGCGAC
CGCCACGCGC
ACTCTTCCTC
CGCGGTGGCG
CGGCCCGCGC
CCTCCTGGCG
GCCCGACCAC
CGAGCGCGCC
CGAGCGGCTC
GTGCATGACC
CTGCCTATCA
ATCTTTTTCC
CTGGCTAATA
CACTCGGAAG
AGAGTTTGGC

AAGGCAGTCT
CCTCTGGCCT
TGGCCCCTTC
GCTCGCGTCG
GGACAGCACC
TTGCTCCTTC
GGGCGGGCTC
GCTTCAAAAG
CTGCAGCCCA
GACGTCCCCA
CACACCGTCG
ACGCGCGTCG
GTCTGGACCA
ATGGCCGAGT
CCGCACCGGC
CAGGGCAAGG
GGGGTGCCCG
GGCTTCACCG
CGCAAGCCCG
GAAGGTGGTG
CTCTGCCAAA
AAGGAAATTT
GACATATGGG
AACATATGCC
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GGAGCATGCG
CGCACACATT
GCGCCACCTT
TGCAGGACGT
GCTGAGCAAT
GCTTTCTGGG
AGGGGCGGGG
CGCACGTCTG
AGCTTACCAT
GGGCCGTACG
ATCCGGACCG
GGCTCGACAT
CGCCGGAGAG
TGAGCGGTTC
CCAAGGAGCC
GTCTGGGCAG
CCTTCCTGGA
TCACCGCCGA
GTGCCTGAAT
GCTGGTGTGG
AATTATGGGG
ATTTTCATTG
AGGGCAAATC
CATATGCTGG

CTTTAGCAGC
CCACATCCAC
CTACTCCTCC
GACAAATGGA
GGAAGCGGGT
CTCAGAGGCT
CGGGCGCCCG
CCGCGCTGTT
GACCGAGTAC
CACCCTCGCC
CCACATCGAG
CGGCAAGGTG
CGTCGAAGCG
CCGGCTGGCC
CGCGTGGTTC
CGCCGTCGTG
GACCTCCGCG
CGTCGAGGTG
CCGTCGAGGA
CCAATGCCCT
ACATCATGAA
CAATAGTGTG
ATTTAAAACA
CTGCCATG
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RNA Sequencing data of Aβ1-42 vs H9
Table includes differentially expressed genes with a fold change = |1.5| and a
false discovery rate <0.05.
ID
AGTR2
ANKRD20A12P
AQP3
ARC
AVPR1A
BARX1
C7
CALHM2
CLDN6
COL13A1
COL6A3
COLEC10
CPNE6
DACH1
DIO3
DLK1
EDNRB
FAM150A
FENDRR
FOSB
GATA2
GEM
HBD
HS3ST2
HSPA6
ID1
IL11
IRX4
NPAS4
NPTX1
NR1H4
NR4A1
PITX1
PLAT
PRELP
PRR32

Fold Change (FC)
4.47
3.12
2.22
2.85
1.95
1.79
2.11
1.74
2.57
2.28
2.38
2.11
2.35
2.69
3.01
3.92
9.58
2.97
2.79
2.69
2.46
4
12.38
2.69
3.92
2.99
2.53
1.64
2.62
2.95
4.44
2.79
2.5
2.91
2.53
2.08

p-value
0.000000238
0.000000142
0.000103
0.0000172
0.00000309
0.00023
0.000189
0.0000722
0.000179
0.0000655
2.55E-08
0.0000285
0.0000956
0.0000704
7.57E-09
0.000000105
7.63E-28
0.000000209
0.000000107
0.00000439
0.0000176
0.000000224
2.23E-13
0.0000365
8.1E-13
0.0000923
0.00000297
0.000132
0.000121
0.000000166
9.74E-19
0.0000173
4.51E-08
0.0000164
3.31E-08
0.00006
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False Discovery Rate (q)
0.000167
0.000118
0.023
0.00583
0.00161
0.0415
0.0363
0.018
0.0352
0.0169
0.0000359
0.00883
0.0218
0.0179
0.0000126
0.0000927
6.97E-24
0.000159
0.0000927
0.00216
0.00583
0.000164
6.79E-10
0.0106
1.85E-09
0.0216
0.0016
0.0283
0.0264
0.000132
5.93E-15
0.00583
0.0000549
0.00583
0.0000432
0.0159

RARRES2
SLITRK6
SP8
TBX3
TBX4
UTF1
ZNF253
ZNF732
ZPLD1
AKAP14
ANXA13
APOH
C10orf105
C10orf11
C11orf88
C14orf105
C4BPA
C5orf66
CD36
CFAP161
CLIC5
COL8A1
CXorf57
DAW1
DGKK
EGFLAM
FAM166B
FAM216B
FMO1
FNDC1
FOXG1
GALNT3
GAS2L2
GDA
HP
INSRR
JPH2
KCNMB1
LINC00880
LINC00930
LINC01132

3.66
2.08
2.36
2.07
1.55
2.13
9.06
1.78
1.97
-2.23
-3.53
-2.25
-3.53
-2.06
-1.78
-2.75
-2
-2.41
-4.17
-2.71
-3.66
-1.99
-1.61
-3.61
-2.28
-1.68
-2.57
-3.27
-1.73
-1.95
-2.2
-2.89
-1.95
-3.1
-3.16
-3.07
-2.04
-1.79
-2.3
-1.93
-2.17

0.000000278
0.00000549
1.89E-14
0.000187
0.000203
0.0000345
0.00000246
0.00000195
0.0000787
0.000286
7.15E-08
0.000105
0.000136
0.000169
0.000285
0.00000924
0.0000202
0.0000941
1.03E-09
0.0000425
0.000000493
0.0000119
1.06E-09
0.0000657
0.000000382
0.000156
0.000254
1.79E-08
5.92E-08
0.000156
0.00000694
0.000154
0.000209
0.0000447
0.0000172
0.000014
0.00000921
0.000000102
0.00000493
0.0000451
0.000141
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0.000188
0.00257
6.92E-11
0.0363
0.0382
0.0102
0.00136
0.00111
0.0192
0.0497
0.0000768
0.0231
0.0288
0.0339
0.0497
0.00401
0.00658
0.0218
0.00000194
0.0119
0.00031
0.00488
0.00000194
0.0169
0.000249
0.0317
0.0455
0.0000273
0.0000676
0.0317
0.00317
0.0317
0.0386
0.0123
0.00583
0.00526
0.00401
0.0000927
0.00237
0.0123
0.0295

LINC01139
LOC200726
LRRC71
MAOA
MMRN1
NDST4
NME8
NPY6R
NTRK1
OMD
PCDHB17P
SERPIND1
SHISA2
SLC12A1
STXBP6
TMC5
USH2A
ZNF135
ZNF506
ZNF542P
ZNF582
ZNF582-AS1
ZNF585B

-4.53
-1.67
-2.66
-1.92
-2.43
-2.27
-2.19
-1.72
-3.03
-1.58
-2.33
-3.2
-2.14
-3.05
-3.53
-2.45
-1.83
-7.06
-2.2
-3.27
-2.01
-1.95
-3.1

0.00000112
0.0000386
0.0000492
0.0000141
0.000207
0.000259
0.000229
0.0000847
0.0000125
0.0000309
0.000179
0.0000315
0.00000323
0.000000104
0.000000536
0.0000729
0.0000103
6.4E-13
1.47E-17
4.62E-30
0.0000122
0.0000224
0.000201

0.00066
0.011
0.0132
0.00526
0.0386
0.0459
0.0415
0.0204
0.00488
0.00941
0.0352
0.00941
0.00164
0.0000927
0.000326
0.018
0.00437
1.67E-09
6.72E-14
8.43E-26
0.00488
0.00718
0.0382

RNA Sequencing data of Aβ1-40 vs H9
Table includes differentially expressed genes with a fold change = |1.5| and a
false discovery rate <0.05.
ID
AGTR2
ANGPTL1
ANKRD20A12P
AVPR1A
C7
CALB1
COL6A3
CSRP1
CXorf57
DIO3
DLK1

Fold Change(FC)
2.04
2.23
3.68
2
2.39
2.17
5.66
3.14
3.48
3.76
3.18

p-value
0.0000353
0.0000946
4.11E-09
0.0000317
0.0000402
0.000144
1.39E-08
1.38E-09
4.38E-11
0.00000177
0.00009
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False Discovery Rate (q)
0.0143
0.032
0.00000683
0.0135
0.016
0.0425
0.0000169
0.00000315
0.000000133
0.00108
0.031

DNAJA4
EDNRB
FAM150A
FENDRR
GATA2
GDF10
GEM
GFAP
H19
HSPA6
IRS4
LGR5
PRODH
LRRC61
NPTX1
NR1H4
PAX2
PITX1
PLAT
PNPLA4
POTEM
POU4F1
PRELP
RARRES2
S100A6
SERPINE1
SIX6
SLC14A1
SLITRK6
SST
SYT10
TBX3
TBX4
TCEAL5
TNFRSF11B
TRIM58
VAMP5
ZFP3
ZIC4
ZNF253
ZNF595

2.93
3.71
2.38
2.93
4.11
2.73
2.85
2.17
71.51
2.25
4.03
1.62
2.41
2.25
2.69
5.46
2.48
2.51
2.22
7.62
2.1
2
2.25
2.38
4.53
3.76
6.77
1.64
2.19
1.75
2.71
3.25
2.22
4.03
3.07
3.56
4.14
4.56
1.96
9.51
2.58

0.00000264
2.9E-21
0.000143
1.12E-08
0.00000133
0.000000176
0.0000706
0.000000551
8.06E-58
0.00000581
0.000000485
0.0000537
0.000111
4.77E-08
0.0000268
7.9E-17
1.74E-08
6.67E-08
0.0000516
7.79E-24
0.0000681
0.000111
0.00000348
0.00000124
3.34E-09
0.0000311
0.000000339
0.0000432
0.0000214
0.000135
0.0000242
0.0000726
0.00000033
0.000000281
0.0000047
1.32E-08
0.000141
8.63E-09
0.000116
0.0000165
0.00000976
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0.00155
1.77E-17
0.0425
0.0000158
0.000837
0.000146
0.0253
0.000373
1.47E-53
0.00312
0.00034
0.02
0.0363
0.0000484
0.012
2.88E-13
0.0000199
0.0000641
0.0196
7.11E-20
0.0249
0.0363
0.00198
0.000807
0.00000609
0.0135
0.000247
0.0168
0.0103
0.0417
0.0113
0.0255
0.000247
0.000223
0.0026
0.0000169
0.0425
0.0000131
0.0368
0.00835
0.00509

ZNF680
ZNF790-AS1
ZSCAN1
BEX5
C4BPA
LINC01139
LINC01146
MLC1
NPY6R
PENK

3.78
2.71
3.32
-10.7
-2.5
-9.92
-3.66
1.44
-2.22
-2.83

7.43E-21
5.76E-11
0.000000111
8.26E-08
0.0000348
3.21E-09
0.000117
0.0000253
0.0000204
3.21E-08
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3.39E-17
0.00000015
0.0000965
0.0000754
0.0143
0.00000609
0.0368
0.0116
0.01
0.0000345
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